tbuckley/cabot-search huggingface dataset:
Current epidemiology and clinical characteristics of autoimmune liver diseases in South Korea
Authors: Sook-Hyang Jeong
Journal: Clinical and Molecular Hepatology (2018)

Autoimmune liver diseases including autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC) are rare diseases. The aim of this review is to examine the epidemiology and clinical characteristics of AIH and PBC in South Korea. There were 4,085 patients registered as AIH in the Rare Intractable Disease Registry of Korea between 2009-2013, with a median age of 56 years and female-to male ratio of 6.4. The age-adjusted incidence and prevalence of AIH were 1.07/100,000/year and 4.82/100,000 persons, respectively. Among the patients, 1.1% underwent liver transplantation, and case fatality was 2.18%. Liver cirrhosis at diagnosis was accompanied in 23%; liver biopsy was performed in 75.2%, and prednisolone therapy or prednisolone and azathioprine combination therapy was done in 73% with a remission rate of 86%. There were 2,824 patients with PBC (≥20 years) registered in Korea between 2009-2013 with a median age of 57 years and female-to male ratio of 6.2. The age-adjusted incidence and prevalence of PBC were 0.86/100,000/year and 4.75/100,000 persons, respectively. Among the patients, 2.5% underwent liver transplantation, and case fatality was 2.2% with a 5-year transplantation-free survival of 95.4%. Ursodeoxycholic acid (UDCA) was prescribed in 90% of the patients with a UDCA inadequate response rate of 30%. In conclusion, AIH and PBC are rare but mostly treatable diseases if diagnosed in the early stages. However, scarce data, low awareness, delayed diagnosis and non-availability of 2nd line therapeutics are important issues to be solved. Therefore, governmental support for research and drug development and nationwide cooperative studies are warranted. Keywords: Autoimmune hepatitis; Primary biliary cholangitis; Simplified scoring system; Autoantibody; Liver transplantation
Abstract 18856: Patients With Mild Congenital Heart Disease Lesions Are at High Risk of Infective Endocarditis: A UK Tertiary Centre Experience
Authors: Athanasios Koutsoukis, Rhian Lakhani, Natali Chung, Yaso Emmanuel, Christoph Kiesewetter, Cathy Head, Bernard Prendergast, John Chambers, David Anderson, Conal Austin, Alessandra Frigiola
Journal: Circulation (2016)

Introduction: Infective Endocarditis (IE) is a serious complication in patients with congenital heart disease (CHD). This study reviews the characteristics of patients with IE and CHD presenting to...
Standardized Handoffs in the Intensive Care Unit
Authors: Amalia Cochran
Journal: JAMA Surgery (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Thy1-Targeted Microbubbles for Ultrasound Molecular Imaging of Pancreatic Ductal Adenocarcinoma
Authors: Lotfi Abou-Elkacem, Huaijun Wang, Sayan M. Chowdhury, Richard H. Kimura, Sunitha V. Bachawal, Sanjiv S. Gambhir, Lu Tian, Jürgen K. Willmann
Journal: Clinical Cancer Research (2018)

Purpose: To engineer a dual human and murine Thy1-binding single-chain-antibody ligand (Thy1-scFv) for contrast microbubble-enhanced ultrasound molecular imaging of pancreatic ductal adenocarcinoma (PDAC).Experimental Design: Thy1-scFv were engineered using yeast-surface-display techniques. Binding to soluble human and murine Thy1 and to Thy1-expressing cells was assessed by flow cytometry. Thy1-scFv was then attached to gas-filled microbubbles to create MBThy1-scFv Thy1 binding of MBThy1-scFv to Thy1-expressing cells was evaluated under flow shear stress conditions in flow-chamber experiments. MBscFv-scrambled and MBNon-targeted were used as negative controls. All microbubble types were tested in both orthotopic human PDAC xenografts and transgenic PDAC mice in vivoResults: Thy1-scFv had a KD of 3.4 ± 0.36 nmol/L for human and 9.2 ± 1.7 nmol/L for murine Thy1 and showed binding to both soluble and cellularly expressed Thy1. MBThy1-scFv was attached to Thy1 with high affinity compared with negative control microbubbles (P < 0.01) as assessed by flow cytometry. Similarly, flow-chamber studies showed significantly (P < 0.01) higher binding of MBThy1-scFv (3.0 ± 0.81 MB/cell) to Thy1-expressing cells than MBscFv-scrambled (0.57 ± 0.53) and MBNon-targeted (0.43 ± 0.53). In vivo ultrasound molecular imaging using MBThy1-scFv demonstrated significantly higher signal (P < 0.01) in both orthotopic (5.32 ± 1.59 a.u.) and transgenic PDAC (5.68 ± 2.5 a.u.) mice compared with chronic pancreatitis (0.84 ± 0.6 a.u.) and normal pancreas (0.67 ± 0.71 a.u.). Ex vivo immunofluorescence confirmed significantly (P < 0.01) increased Thy1 expression in PDAC compared with chronic pancreatitis and normal pancreas tissue.Conclusions: A dual human and murine Thy1-binding scFv was designed to generate contrast microbubbles to allow PDAC detection with ultrasound. Clin Cancer Res; 24(7); 1574-85. ©2018 AACR.
Executive Summary of the 2017 ESCMID -ECMM Guideline for the Diagnosis and Management of Aspergillus Disease
Authors: Andrew J. Ullmann, Jose M. Aguado, Sevtap Arikan-Akdagli, David W. Denning, Andreas H. Groll, Katrien Lagrou, Cornelia Lass-Flörl, Russel E. Lewis, Patricia Munoz, Paul E. Verweij, Adilia Warris, Florence Ader, Murat Akova, Maiken C. Arendrup, Rosemary A. Barnes, Catherine Beigelman-Aubry, Stijn Blot, Emilio Bouza, Roger J. M. Bruggemann, Dieter Buchheidt, Jacques Cadranel J, Elio Castagnola, Arunaloke Chakrabarti, Manuel Cuenca-Estrella, George Dimopoulos, Jesus Fortun, Jean-Pierre Gangneux, Jorge Garbino, Werner J. Heinz, Raoul Herbrecht, Claus P. Heussel, Chris Kibbler, Nikolay Klimko, Bart-Jan Kullberg, Christoph Lange, Thomas Lehrnbecher, Jürgen Löffler, Olivier Lortholary, Johan Maertens, Oscar Marchetti, Jacques F. G. M. Meis, Livio Pagano, Patricia Ribaud, Malcolm Richardson, Emmanuel Roilides, Markus Ruhnke, Maurizio Sanguinetti, Donald C. Sheppard, János Sinkó, Anna Skiada, Maria J. G. T. Vehreschild, Claudio Viscoli, Oliver A. Cornely
Journal: Clinical Microbiology and Infection (2018)
New Deputy Editor—January 2018
Authors: Melina R. Kibbe
Journal: JAMA Surgery (2018)

JAMA Surgery thanks Julie Ann Sosa, MD, MA, for her tremendous service as Deputy Editor from 2015 through 2017. Dr Sosa will be assuming the role of Editor in Chief for The World Journal of Surgery effective January 1, 2018. We wish Dr Sosa all the best in her new adventure. She will be missed!
Healthy Lifestyle for All Through Patient Care and Policy
Authors: Sherry L. Pagoto, Gary G. Bennett
Journal: JAMA Internal Medicine (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Six-Year Diabetes Incidence After Genetic Risk Testing and Counseling: A Randomized Clinical Trial
Authors: Jason L. Vassy, Wei He, Jose C. Florez, James B. Meigs, Richard W. Grant
Journal: Diabetes Care (2018)

Genetics determine only a small proportion of common disease risk, but the potential to motivate health behavior change remains a proposed benefit of genetic susceptibility testing. Evidence supporting this benefit is scant (1), and studies of long-term clinical outcomes are absent. Type 2 diabetes is heritable yet preventable by behavior change. Although genetic scores predict incident diabetes (2), we demonstrated in the Genetic Counseling/Lifestyle Change (GC/LC) Study that learning one’s genetic risk did not impact short-term weight loss or behavior change motivation among participants in a diabetes prevention program (3). Here, we examine 6-year diabetes incidence among participants.

The GC/LC Study was a randomized trial of diabetes genetic risk counseling among primary care patients (3). Eligible participants did not have diabetes but were at high phenotypic risk for diabetes in that they were overweight and met at least one other metabolic syndrome criterion. Participants were randomized to undergo genotyping for a diabetes genetic risk score (tested) versus no genotyping (control). Tested participants in …
Cerebral Embolism Following Transcarotid Transcatheter Aortic Valve Replacement
Authors: Chekrallah Chamandi, Siamak Mohammadi, Eric Dumont, Daniel Doyle, Robert DeLarochellière, Jean-Michel Paradis, Rishi Puri, Sergio Pasian, Émilie Pelletier-Beaumont, Josep Rodés-Cabau
Journal: Journal of the American College of Cardiology (2018)
Personalized Surgical Care for Older Adults
Authors: Gerard M. Doherty
Journal: JAMA Surgery (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Reduction of Immunosuppression after Disease-Specific Donor Cell Chimerism Decrease Can Prevent Hematological Relapse Following Allogeneic Stem Cell Transplantation after Non-Myeloablative (NMA) Conditioning — Results of a Prospective Phase II Study. Eudract #: 2007-002420-15
Authors: Vladan Vucinic, Saskia Hell, Madlen Jentzsch, Michael Cross, Sabine Leiblein, Wolfram Pönisch, Georg-Nikolaus Franke, Gerhard Behre, Thoralf Lange, Sebastian Schwind, Dietger Niederwieser
Journal: Blood (2017)
Starting long acting bronchodilators for COPD is associated with increased cardiovascular risk, finds study
Authors: Susan Mayor
Journal: BMJ (2018)

Initiating treatment of chronic obstructive pulmonary disease (COPD) with a long acting β2 agonist or a long acting antimuscarinic antagonist is associated with a 50% higher risk of serious cardiovascular events, including in patients with no previous cardiovascular disease, a large case-control study has found.1

Inhaled long acting bronchodilators are the standard treatment for COPD, and data on cardiovascular risk has been mixed.

Researchers used data from the Taiwan National Health Insurance …
RNA sequencing for early response analysis to chemotherapy in gastric cancer.
Authors: Christoph Johannes Treese, Martin Kerick, Christian Barmeyer, Bernd Timmermann, Moritz von Winterfeld, Michal Ruth Schweiger, Severin Daum
Journal: Journal of Clinical Oncology (2015)

e15051 Background: Response to chemotherapy is a prognostic factor for patients with gastric cancer (GaCa). No biomarkers exist to predict response to chemotherapy despite a number of expression studies on the subject. We analyzed early response to chemotherapy by sequential RNA sequencing, pre- and post-therapy as a proof of principle study. Methods: Ten patients with local advanced GaCa were included.Tumor and benign tissues were endoscopically biopsied before and after the first cycle of chemotherapy. After 3 cycles, tumors were resected and evaluated as 3 responders (R) and 7 non-responders (NR). After RNA sequencing an ANOVA was calculated including response and treatment. We focused on hallmarks of cancer genes to reduce the impact of transcriptional passenger signatures and compared benign, R and NR profiles using principal component analysis (PCA). Results: Pre-therapeutic expression profiles of tumor and benign tissue reflected the loss of complexity of tumor compared to benign tissues with a dispersed PCA profile for healthy tissues as opposed to the centered profile found for tumor tissues. Pre-therapeutic profiles of R were clustered but similar to profiles of NR which confirmed the difficulty of pre-therapeutic classification and explains the current lack of biomarkers. Hallmarks of cancer genes with differential response under chemotherapy were predominantly down-regulated in R vs. NR (OR: 2; p: 1.2e-6). In detail, genes implicated in proliferation (OR: 8.3; p: 2.1e-16), invasion and metastasis (OR: 3.6; p: 4.3e-10), tumor promoting inflammation (OR: 4.2; p: 3.2e-6) and oncogenes (OR: 2; p: 0.02) were significantly down-regulated in R. Conclusions: We could demonstrate that sequential expression screening of endoscopic biopsies resulted in differential overall response in R versus NR. Pre-therapeutic heterogeneous tumors could be identified as R by their homogeneous reaction to chemotherapy. Additional insight in molecular mechanisms provided tumor hallmarks as key structures disturbed in differential therapy response with energy metabolism as central mechanism. Our data suggest, that studying the individual reaction to therapy on a mechanistic level can predict response to improve prognosis and therapies.
Targeted mRNA Therapy for Ornithine Transcarbamylase Deficiency
Authors: Mary G. Prieve, Pierrot Harvie, Sean D. Monahan, Debashish Roy, Allen G. Li, Teri L. Blevins, Amber E. Paschal, Matt Waldheim, Eric C. Bell, Anna Galperin, Jean-Rene Ella-Menye, Michael E. Houston
Journal: Molecular Therapy (2018)

We describe a novel, two-nanoparticle mRNA delivery system and show that it is highly effective as a means of intracellular enzyme replacement therapy (i-ERT) using a murine model of ornithine transcarbamylase deficiency (OTCD). Our Hybrid mRNA Technology delivery system (HMT) comprises an inert lipid nanoparticle that protects the mRNA from nucleases in the blood as it distributes to the liver and a polymer micelle that targets hepatocytes and triggers endosomal release of mRNA. This results in high-level synthesis of the desired protein specifically in the liver. HMT delivery of human OTC mRNA normalizes plasma ammonia and urinary orotic acid levels, and leads to a prolonged survival benefit in the murine OTCD model. HMT represents a unique, non-viral mRNA delivery method that allows multi-dose, systemic administration for treatment of single-gene inherited metabolic diseases.
CD4+ and CD8+CD60+CD45RO+IL-4+IFNγ- T Cells Expressing Receptors for Complement Split Product (CSP) C3a, but Not C5a, Are Increased in Blood of Serum IgE+, Compared With Serum IgE- Adults
Authors: Lucius DeGregorio, Timothy D. Morello, Seto M. Chice, Maja Nowakowski, Tehila A. Saadia, Tamar A. Smith-Norowitz, Rauno Joks, Helen G. Durkin
Journal: Journal of Allergy and Clinical Immunology (2018)
B-cell activating factor/Th17/Neutrophils axis plays a role in refractory nasal polyposis
Authors: Dong-Kyu Kim, Gwanghui Ryu, Sang Duk Hong, Il Gyu Kong, Seung Kyu Chung, Jae Seo Lee, Hun Jong Dhong, Dae Woo Kim
Journal: Journal of Allergy and Clinical Immunology (2018)
<i>Notes from the Field</i>: Investigation of Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Among Patients at a Community Hospital — Kentucky, 2016
Authors: Sae-Rom Chae, Anna Q. Yaffee, Mark K. Weng, D. Cal Ham, Kimberly Daniels, Amanda B. Wilburn, Kimberly A. Porter, Andrea H. Flinchum, Sandra Boyd, Alicia Shams, Maroya S. Walters, Alexander Kallen
Journal: MMWR Morbidity and Mortality Weekly Report (2018)
Abstract 16144: Association Between Elevated Initial Trauma Center Body Temperature and Non-mortality Outcomes Following Major Traumatic Brain Injury
Authors: Joshua B Gaither, Vatsal Chikani, Daniel W Spaite, Jennifer J Smith, Merlin Curry, Moses Mhayamaguru, Bruce Barnhart, P. David Adelson, Chad Viscusi, Kurt Denninghoff, Bentley J Bobrow
Journal: Circulation (2015)

Introduction: During prolonged hospitalization for Traumatic Brain Injury (TBI), fever has been identified as a possible cause of secondary brain injury and previous reports have identified an association between elevated body temperature and increased mortality following TBI. However, little is known about the relationship between an elevated initial trauma center body temperature (ITCT), measured immediately after EMS transport, and non-mortality outcomes. The purpose of this study was to determine if a correlation exists between elevated ITCT and various important patient outcomes. Methods: All moderate/severe TBI cases (CDC Barell Matrix Type 1) in the Arizona State Trauma Registry (ASTR; 1/1/07-12/31/12) were analyzed by the following ITCT categories: 36.5-37.9°C (normal-NT), 38.0-38.9°C (elevated-ET) and ≥39.0°C (very elevated-VET). Outcomes included: Trauma Center (TC) length-of-stay (LOS), Intensive Care Unit (ICU) LOS, and total TC charges. For continuous variables, non-parametric Kruskal-Wallis test was used to assess the median difference between the ET and VET cohorts and the NT group (reference). Wilcoxon two-sample tests identified groups with significant differences (alpha = 0.05). Results: 22,925 cases met inclusion criteria (exclusions: missing ITCT-2,885; missing demographics-700; ITCT &lt;36.5°C - 8953). Both ET and VET had significantly longer TC LOS/ICU LOS and higher total hospital charges compared to the NBT group (all p values &lt;0.0001; Figure 1). Conclusion: In this statewide study, ET or VET were associated with longer ICU LOS, longer hospital LOS and increased hospital charges. Future work is needed to identify the causes of temperature elevations that occur during prehospital TBI care (e.g., environmental factors versus autonomic dysregulation) and whether initiation of in-field measures to prevent temperature elevation might improve outcome.
X chromosomal linkage to eosinophilic esophagitis susceptibility
Authors: Leah C. Kottyan, Avery Maddox, Kate Hoffman, Leanne Ray, Carmey Forney, Michael Eby, Melissa K. Mingler, Kenneth Kaufman, Phillip Dexheimer, Nina Lukac, Julie M. Caldwell, Mark Rochman, Tetsuo Shoda, Ting Wen, Justin C. Wheeler, Simon P. Hogan, Vincent A. Mukkada, Philip E. Putnam, Pablo P. Abonia, Robert M. Genta, Lisa J. Martin, Evan S. Dellon, Marc E. Rothenberg
Journal: Journal of Allergy and Clinical Immunology (2018)
Donor EBV-Positive Serostatus Increases the Risk of Chronic GVHD in Patients with Myeloid and Lymphoid Malignancies Other Than Acute Leukemia: Infectious Diseases Working Party EBMT Study
Authors: Jan Styczynski, Gloria Tridello, Nina Knelange, Per T. Ljungman, Lidia Anna Gil, Malgorzata Mikulska, Gerard Socie, Patrice Chevallier, Didier Blaise, Ibrahim Yakoub-Agha, Noel Milpied, Jan J. Cornelissen, Johan Maertens, Eefke Petersen, Veronique Leblond, Joan Hendrik Veelken, Michel Schaap, Jakob R. Passweg, Mauricette Michallet, Nathalie Fegueux, Eric Deconinck, Nigel H. Russell, Grzegorz Basak, Silvia Montoto, Nicolaus Kröger, Simone Cesaro
Journal: Blood (2017)
Standard chemoradiation in combination with VEGF targeted therapy for glioblastoma results in progressive gray and white matter volume loss
Authors: Morgan L Prust, Kourosh Jafari-Khouzani, Jayashree Kalpathy-Cramer, Pavlina Polaskova, Tracy T Batchelor, Elizabeth R Gerstner, Jorg Dietrich
Journal: Neuro-Oncology (2017)
Association of Breast Implants With Anaplastic Large-Cell Lymphoma
Authors: Colleen M. McCarthy, Steven M. Horwitz
Journal: JAMA Oncology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Extracellular vesicles as mediators of the progression and chemoresistance of pancreatic cancer and their potential clinical applications
Authors: Jiangdong Qiu, Gang Yang, Mengyu Feng, Suli Zheng, Zhe Cao, Lei You, Lianfang Zheng, Taiping Zhang, Yupei Zhao
Journal: Molecular Cancer (2018)

Pancreatic cancer is one of the most lethal cancers worldwide due to its insidious symptoms, early metastasis, and chemoresistance. Hence, the underlying mechanisms contributing to pancreatic cancer progression require further exploration. Based on accumulating evidence, extracellular vesicles, including exosomes and microvesicles, play a crucial role in pancreatic cancer progression and chemoresistance. Furthermore, they also possess the potential to be promising biomarkers, therapy targets and tools for treating pancreatic cancer. Therefore, in-depth studies on the role of extracellular vesicles in pancreatic cancer are meaningful. In this review, we focus on the regulatory effects of extracellular vesicles on pancreatic cancer progression, metastasis, cancer-related immunity and chemoresistance, particularly their potential roles as biomarkers and therapeutic targets.